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exist. The publication is likely to influence
the attitudes of cardiac surgeons and may
jeopardize future better-designed and better-
executed RCTs of an important question.
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Reply to the Editor:
We thank Professor Angelini and col-
leagues for raising several important issues
in relation to our trial.1 However, we do not
agree that the conclusion of our article is
misleading, and we believe that the issues
raised in their letter can be simply and
easily addressed.
The article presents the results 5 years
after trial inception. We make that perfectly
clear in the text and display the mean du-
ration of follow-up in a graphic format with
the Kaplan-Meier graphs. Pocock’s con-
cerns about the imprecision of estimates as
displayed by such graphs in the presence of
few events relates to the risk of conveying
a visual impression of a difference where
none exists. This is of moot concern in a
graphic display of actual lack of differ-
ence.2
This interim analysis was not planned;
it represented a response of the group of
cardiac surgeons, cardiologists, intensiv-
ists, and cardiac anesthesiologists involved
in the trial to the aggressively promoted
view that radial artery conduits are “best,”
a view also strongly espoused by Professor
Angelini and colleagues3 on the basis of
nonrandomized data. A decision to under-
take an interim 5-year graft patency analy-
sis was made to ensure that, with the best of
the data available so far, the design of the
trial did not expose our patients to “unsafe
surgical practice.” No criteria were for-
mally set for “stopping” the trial. The data
were presented to the physicians involved
in the trial and, following discussion, a
unanimous decision was made to continue
the study. The enrollment of 556 patients is
now complete.
We agree about the importance of in-
terim analyses for the purpose of patient
safety. However, the methodology sug-
gested by the correspondents is typically
that of large multicenter drug company-
sponsored trials, where major financial
conflicts of interest exist. In such studies,
the need for an impartial Data and Safety
Monitoring Board (DSMB) is obvious. The
need for a DSMB in single-center studies,
where the patients are known to all physi-
cians involved and are regularly seen in
outpatient clinics, is empirically unproven.
Furthermore, the statistical criteria for ac-
tion cannot, in our opinion, be sensibly
taken as an absolute but must be seen
within a Bayesian analysis of the pretest
probability of a particular outcome being
correct.4 We note that no gold standard
exists to empirically validate the sensitivity
and specificity of current statistical criteria
for trial cessation. The probabilities of a
difference between groups1 approximate
unity, a far cry from the extreme statistical
“stopping” values as suggested by O’Brien
and Fleming and the Peto-Haybittle rule to
avoid a type 1 error.5,6
Our study might be underpowered.
However, the number of events seen in this
interim group of patients may not be rep-
resentative of the whole population. Fur-
thermore, we anticipate that most of the
outcome events will be seen in the latter
half of the trial, and therefore, the estima-
tion of sample size based on information
from the interim analysis is inappropriate.
We invite caution and consider that more
interim information is needed before a re-
calculation of sample size is necessary. We
agree that our report contains data with
limited statistical power. As this was a
safety analysis aimed at excluding only a
major difference between the 2 groups, we
believe our observations are important to
the continued conduct of this and other
studies, hence the publication.
All 438 patients1 were included in the
clinical outcomes analyses, which were
based on an “intention-to-treat.” Forty-two
patients were excluded from the graft pa-
tency study: 21 were radial artery trial
grafts and 21 were controls (16 right inter-
nal thoracic artery and 5 saphenous vein
grafts). Two patients of the 42 refused an-
giography and 23 were excluded because
of graft disease. In 2 patients the wrong
conduit was used and in the remaining 15
patients, the correct grafts were used, al-
TABLE 1. Power* of comparisons based on different sample sizes and cumulative event rates
Cumulative
event rate
at 10 years
in RITA
group (%)
Number of patients per group
200 300 400 500 600 700 800 900 1000 1200 1400 1600 1800 2000
12 17.7 24.2 30.7 36.9 42.9 48.6 53.8 58.8 63.3 71.2 77.7 82.9 87.0 90.2
16 23.9 33.3 42.3 50.6 58.0 64.6 70.4 75.4 79.7 86.4 91.0 94.2 96.3 97.7
RITA, Right internal thoracic artery.
*Power estimates assume: (1) recruitment over 6 years, (2) maximum duration of follow-up of 10 years, (3) 5% significance level (2-tailed), (4) analysis by
log rank test.
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though the surgical technique was not as
defined in the protocol. We understand the
correspondents’ concern about possible se-
lection bias due to the exclusion of patients
who did not receive the correct graft or in
whom the surgeon did not target the correct
artery. However, such decision is logical
because it is not reasonable to assess the
patency of a radial graft when no such graft
exists. The same applies to assessing flow
to a vascular bed that was actually not
grafted. We consider that, in a study such
as this, angiographic analysis on “per-treat-
ment” principles is the correct approach.
We further note that this decision was
made a priori.
Finally, the conclusions of the article
are correct given the data available. Fur-
thermore, all the necessary information is
available in detail for readers to understand
the limitations that surround such conclu-
sions. There is no attempt to mislead and
whether our report will influence surgical
attitudes remains uncertain. Furthermore, it
is an “open verdict” and we cannot see how
it could jeopardize future randomized con-
trolled trials, given our conclusion that “the
continued evaluation of the RA is justi-
fied.” For our part, we are very committed
to carrying out good randomized trials in
cardiac surgery and will continue to do so
in a branch of medicine where, relatively
speaking, they are uncommon.
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Reply to the Editor:
The choice between the right internal tho-
racic artery (RITA) or radial artery (RA)
for the second coronary artery bypass con-
duit remains hotly debated, as evidenced
by 2 recent publications in the Journal, one
a randomized controlled trial1 and the other
a retrospective observational study.2
The interim 5-year result of our ran-
domized controlled study suggested that
the clinical outcomes of the RITA and the
RA groups were similar. This differed from
the conclusion drawn from the cohort study
reported by Caputo and colleagues,2 which
suggested a clinical benefit from using the
RA compared with the RITA. It is impor-
tant to consider possible reasons for such
an apparent difference in conclusions.
Caputo and colleagues’ study2 differed
from the randomized trial. There was no
assessment of graft patency, and they in-
cluded additional end points. Obviously,
cohort studies can never control for unrec-
ognized factors. Therefore, an observa-
tional study should always be regarded as
providing less reliable evidence than a ran-
domized trial.3 This has recently been
highlighted by the complete reversal of
opinion as to the benefits of hormone re-
placement therapy once the results of ran-
domized trials became available. One im-
portant factor that may not be well
controlled in an observational study of this
sort is the surgeon. The choice of graft was
“entirely at the discretion of the surgeon.”
If some surgeons strongly preferred one
type of operation, or even used it exclu-
sively, this means that the comparison
based on the observational data may suffer
from bias because of confounding with the
expertise of the surgeon.
Our comparison of cardiac event-free
survival in the randomized controlled trial
showed no significant differences, but this
does not necessarily mean that the 2 studies
are in conflict.
For our RA versus RITA comparison,
the estimates and 95% confidence intervals
(CIs) were 91% (76%-99%) for the RA
group and 82% (63%-99%) for the RITA
group. Because of the small numbers, these
CIs are very wide and therefore consistent
with a number of different possible under-
lying realities (“hypotheses”), namely, that
the RA and RITA have the same cardiac
event-free survival, that the RITA is better
than the RA, and that the RA is better than
the RITA. The latter is suggested by Ca-
puto and coworkers.2 Our study is not yet
in conflict with this because, for example,
our findings are consistent with a “true”
cardiac event-free survival of 90% for the
RA group and 70% for the RITA group;
both of these values are in the respective
CIs, and if they were the true values, which
they could be, that would be consistent
with Caputo and colleagues’ findings.
Biologically, the left internal thoracic
artery and RITA are similar and when
grafted to the left anterior descending and
circumflex coronary arteries4 have almost
identical results. However, when the RITA
is grafted to the right coronary system,
there is a significant reduction in patency.
For example, in the first 5 years of our
internal thoracic artery program from 1984
to 1989, patency of the in situ RITA graft
to the distal right coronary artery or its
branches was approximately 75%. Because
of the high graft failure rate of in situ RITA
grafts when used on the right side, most
surgeons, including ourselves, have fa-
vored using the RITA graft to the left sys-
tem,5 either as a free or in situ graft. This
latter strategy results in better graft survival
curves that separate by 6 years.6 Caputo
and coworkers,2 on the other hand, used an
in situ or pedicled graft in 94% of patients.
Furthermore, 53% of the RITA grafts were
attached to the right coronary or posterior
descending artery where results could be
less than optimal.2 Therefore, although
some of their analyses adjusted for the tar-
get artery and the authors thus claim that
the results were not compromised, it is not
clear whether adjustment was made for the
type of proximal anastomoses (in situ vs
free).
The clinical end point used by Caputo
and colleagues2 was a composite of death,
myocardial infarction, repeat coronary by-
pass or percutaneous coronary interven-
tion, and recurrent angina. Unfortunately,
any composite outcome measure is only as
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